Journal of Molecular Medicine

, Volume 96, Issue 8, pp 753–764 | Cite as

The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling

  • Haiyun Qian
  • Li Chen
  • Jiangping Huang
  • Xianghui Wang
  • Shengwei Ma
  • Fenghe Cui
  • Liyun Luo
  • Li Ling
  • Kai LuoEmail author
  • Guopei ZhengEmail author
Original Article


Recently, emerging evidence has suggested that long noncoding RNAs (lncRNAs) have crucial roles in cancer progression. Here, we demonstrated that the lncRNA MIR4435-2HG was highly expressed in lung cancer tissues and correlated with histological grades and lymph node metastasis. Phenotypic analysis indicated that MIR4435-2HG knockdown inhibited lung cancer cell proliferation and invasion in vitro and in vivo. Notably, MIR4435-2HG knockdown suppressed the EMT (epithelial-mesenchymal transition) process and cancer stem cell traits of lung cancer cells. Mechanistically, MIR4435-2HG knockdown decreased the transactivation of β-catenin. MIR4435-2HG interacted with β-catenin and thus prevented its degradation by the proteasome system. Our findings highlight the important roles and mechanisms of MIR4435-2HG in lung cancer progression. High expression of lncRNA MIR4435-2HG correlates with lung cancer progression MIR4435-2HG promotes lung cancer cells proliferation and invasion MIR4435-2HG knockdown suppresses the EMT process and cancer stem cell traits MIR4435-2HG knockdown inhibits the β-catenin signalling.


Lung cancer lncRNAs EMT β-catenin 


Authors’ contributions statement

HQ, LC, XW, SM, LLuo and LLing performed the research; JH and FC statistically analysed the experimental data; KL and GZ designed the study and wrote the paper.

Funding information

This study was supported by grants from the National Natural Science Foundation of China (81672616 and 81402196) the Guangdong Natural Science Funds for Distinguished Young Scholars, China (2016A030306003), the Science and Technology Program of Guangzhou, China (201710010100), the Guangzhou Municipal University Scientific Research Project (1201610027) and supported by Guangzhou key medical discipline construction project fund.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  2. 2.
    Heist RS, Engelman JA (2012) SnapShot: non-small cell lung cancer. Cancer Cell 21:448 e442CrossRefGoogle Scholar
  3. 3.
    Zhang J, Wang J, Xing H, Li Q, Zhao Q, Li J (2016) Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells. Mol Cell Biochem 411:331–340CrossRefPubMedGoogle Scholar
  4. 4.
    Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P (2013) Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 93:252–259CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ulitsky I, Bartel DP (2013) lincRNAs: genomics, evolution, and mechanisms. Cell 154:26–46CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Batista PJ, Chang HY (2013) Long noncoding RNAs: cellular address codes in development and disease. Cell 152:1298–1307CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Tao H, Zhang JG, Qin RH, Dai C, Shi P, Yang JJ, Deng ZY, Shi KH (2017) LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. Toxicology 386:11–18CrossRefPubMedGoogle Scholar
  8. 8.
    Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C, Wang P, Wang Y, Kong B, Langerød A, Børresen-Dale AL, Kim SK, van de Vijver M, Sukumar S, Whitfield ML, Kellis M, Xiong Y, Wong DJ, Chang HY (2011) Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 43:621–629CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Luo M, Jeong M, Sun D, Park HJ, Rodriguez BA, Xia Z, Yang L, Zhang X, Sheng K, Darlington GJ et al (2015) Long non-coding RNAs control hematopoietic stem cell function. Cell Stem Cell 16:426–438CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB, Boyer LA (2013) Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152:570–583CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Arab K, Park YJ, Lindroth AM, Schafer A, Oakes C, Weichenhan D, Lukanova A, Lundin E, Risch A, Meister M et al (2014) Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Mol Cell 55:604–614CrossRefPubMedGoogle Scholar
  12. 12.
    Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, Yang N, Zhou WP, Yang GS, Sun SH (2014) A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25:666–681CrossRefPubMedGoogle Scholar
  13. 13.
    Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P et al (2015) The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell 16:413–425CrossRefPubMedGoogle Scholar
  14. 14.
    Geisler S, Coller J (2013) RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 14:699–712CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhu H, Zhang L, Yan S, Li W, Cui J, Zhu M, Xia N, Yang Y, Yuan J, Chen X, Luo J, Chen R, Xing R, Lu Y, Wu N (2017) LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle. Oncotarget 8:7867–7877PubMedGoogle Scholar
  16. 16.
    Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM, Xia R, Shu YQ, De W (2015) Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis 6:e1665CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yang Q, Xu E, Dai J, Liu B, Han Z, Wu J, Zhang S, Peng B, Zhang Y, Jiang Y (2015) A novel long noncoding RNA AK001796 acts as an oncogene and is involved in cell growth inhibition by resveratrol in lung cancer. Toxicol Appl Pharmacol 285:79–88CrossRefPubMedGoogle Scholar
  18. 18.
    Deng LL, Chi YY, Liu L, Huang NS, Wang L, Wu J (2016) LINC00978 predicts poor prognosis in breast cancer patients. Sci Rep 6:37936CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Fu M, Huang Z, Zang X, Pan L, Liang W, Chen J, Qian H, Xu W, Jiang P, Zhang X (2018) Long noncoding RNA LINC00978 promotes cancer growth and acts as a diagnostic biomarker in gastric cancer. Cell Prolif 51.
  20. 20.
    Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265–273CrossRefPubMedGoogle Scholar
  21. 21.
    Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890CrossRefPubMedGoogle Scholar
  22. 22.
    Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Deng X, Chen H, Shen B, Peng C, Li H, Zhan Q, Zhu Z (2016) Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma. Oncogene 35:1575–1584CrossRefPubMedGoogle Scholar
  24. 24.
    Chen X, Han H, Li Y, Zhang Q, Mo K, Chen S (2016) Upregulation of long noncoding RNA HOTTIP promotes metastasis of esophageal squamous cell carcinoma via induction of EMT. Oncotarget 7:84480–84485PubMedPubMedCentralGoogle Scholar
  25. 25.
    Terashima M, Tange S, Ishimura A, Suzuki T (2017) MEG3 long noncoding RNA contributes to the epigenetic regulation of epithelial-mesenchymal transition in lung cancer cell lines. J Biol Chem 292:82–99CrossRefPubMedGoogle Scholar
  26. 26.
    Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, Kong J, Ding K, Shen HM, Wu H, Xia D, Wu Y (2017) Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p. Mol Cancer 16:118CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhen T, Dai S, Li H, Yang Y, Kang L, Shi H, Zhang F, Yang D, Cai S, He Y, Liang Y, Han A (2014) MACC1 promotes carcinogenesis of colorectal cancer via beta-catenin signaling pathway. Oncotarget 5:3756–3769CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E, Van Die I (2014) Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/beta-catenin signalling in pancreatic adenocarcinoma. Oncotarget 5:5335–5349CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D, So CW (2010) Beta-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18:606–618CrossRefPubMedGoogle Scholar
  30. 30.
    Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138:51–62CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fang L, Cai J, Chen B, Wu S, Li R, Xu X, Yang Y, Guan H, Zhu X, Zhang L, Yuan J, Wu J, Li M (2015) Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/beta-catenin signalling. Nat Commun 6:8640CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Su J, Wu S, Wu H, Li L, Guo T (2016) CD44 is functionally crucial for driving lung cancer stem cells metastasis through Wnt/beta-catenin-FoxM1-Twist signaling. Mol Carcinog 55:1962–1973CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Haiyun Qian
    • 1
  • Li Chen
    • 2
  • Jiangping Huang
    • 1
  • Xianghui Wang
    • 1
  • Shengwei Ma
    • 1
  • Fenghe Cui
    • 1
  • Liyun Luo
    • 3
  • Li Ling
    • 3
  • Kai Luo
    • 3
    Email author
  • Guopei Zheng
    • 3
    Email author
  1. 1.Department of Cardiothoracic Surgery, Jingzhou Central Hospital, The Second Clinical Medical CollegeYangtze UniversityJingzhouChina
  2. 2.Department of Endocrinology, Jingzhou Central Hospital, The Second Clinical Medical CollegeYangtze UniversityJingzhouChina
  3. 3.Guangzhou Key Laboratory of “Translational Medicine on Malignant Tumor Treatment”Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityGuangzhouChina

Personalised recommendations